COVID-Vaccination Induces RCVS Attacks: A Case Report

Background To describe and discuss the association between COVID-19 vaccination and RCVS attacks in a patient with RCVS and whether targeting angiotensin 2 receptor could be a preventive option. Case presentation A 30-year-old male previously diagnosed with reversible cerebral vasoconstriction syndrome (RCVS), presented to the department of neurology with accumulation of RCVS attacks after receiving the first Pfizer COVID-19 vaccine. The neurologic exam, blood samples, electrocardiogram (ECG), and a computer tomography (CT) of the head were normal. The patient was treated with angiotensin-II receptor antagonist, Losartan, with a good response and was discharged with a prescription for Losartan lasting until three days after the second Pfizer COVID-19 vaccine. No further RCVS attacks were reported. Conclusions Our case suggests that COVID-19 vaccine induces RCVS attacks in susceptible individuals and targeting angiotensin 2 receptor could be a preventive option.